GB Sciences’ CEO John Poss and Chief Science Officer Dr. Andrea Small-Howard Featured at Digital Hollywood’s California Cannabis Forum in Los Angeles

Mr. Poss will speak on GB Sciences’ collaboration with Native Americans in California; Dr. Small-Howard will discuss research to address specific diseases using cannabinoids.

LAS VEGAS, October 10, 2018/PR Newswire/ — GB Sciences, Inc. (OTCQB: GBLX) announces that CEO John Poss and Chief Science Officer Dr. Andrea Small-Howard will be featured on panels at the Digital Hollywood’s California Cannabis Forum at the Skirball Center in Los Angeles.

On October 17th, Dr. Small-Howard will be joined by biopharma research leaders from Phylos Bioscience and Tilray to discuss GB Sciences’ groundbreaking innovations in treating neurological disorders, inflammatory disorders, cardiovascular disease, and chronic pain. In addition, Dr. Small-Howard will speak to the company’s global research footprint, including a new collaboration with the National Kapodistrian University of Athens, Greece to use cultivar analysis to determine treatment applications.

On October 18th, Mr. Poss will speak to GB Sciences’ collaboration with the Los Coyotes Band of Cahuilla & Cupeño Indians, a federally recognized tribe whose 25,000 acre reservation is located in San Diego County. In 2017, GB Sciences and Los Coyotes signed a memorandum of understanding to co-develop cultivation and manufacturing operations on tribal land. Mr. Poss will be joined by tribal leaders from the California Native American Cannabis Association (CNACA) to discuss the opportunities and challenges facing California’s tribes in the cannabis market.

Their participation, which follows on Dr. Small-Howard’s panel at September’s “State of Cannabis” conference in Long Beach, reflects increased GB Sciences visibility and recognition in the California cannabis market.

Digital Hollywood debuted in 1994 and is among the leading entertainment trade conferences; and debuted its Cannabis Forum last year, following adult use legalization. Over 15,000 top executives in the film, television, music, technology and cannabis industries attend Digital Hollywood events annually.

Panel details are below:

Wednesday, October 17

1:45 PM – 2:45 PM

The Science of Medical Cannabis: Matching Strains, Potency and Dosage to Specific Diseases and Disorders

Dr. Andrea Small-Howard, Chief Science Officer, GB Sciences (GBS)

Jessica Assaf, Founder, Cannabis Feminist, co-founder, Hempia

Tim Blake, Founder and Producer, The Emerald Cup

Dr. Catherine Jacobson, Director of Clinical Research, Tilray

Sundarajan Mutialu, Chief Technology Officer and Co-CEO, AZENTIVE

Mowgli Holmes, PhD, co-founder, CEO, Phylos Bioscience

David Traub, Co-Founder, Epiphany Film Fund, Moderator

 

Thursday, October 18

The Luncheon at Skirball Center

12:15 PM – 1:45 PM

Native American Leadership in the Cannabis Industry

Tina Braithwaite, former, Chairwoman, Benton Paiute Tribe

John Poss, CEO, GB Sciences

David Vilapondo, Executive Director, Ilpay Nation, Santa Ysabel Tribal Cannabis Regulatory Agency and Interim Executive Director, California Native American Cannabis Association (CNACA)

Cameron Keluche, President and CEO, KelSie Biotech

Moderator – Amanda Chicago Lewis, Columnist, Rolling Stone

Event registration can be found here: http://www.digitalhollywood.com/CannabisForumFl18.html

About GB Sciences, Inc.

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control.  It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information

Corporate:

GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118

866-721-0297, or

Tom Arcuragi, EVP, tom@gbsciences.com